Yahoo Finance

2024 Full-Year Revenue Growth of +26%

IMPLANET recorded full year revenue of €9.41 million in 2024, compared to €7.45 million in 2023.

Spine Implants activity generated €7.03 million in 2024, compared to €7.07 million in 2023. Meanwhile, the medical equipment distribution activity delivered €2.35 million in 2024, representing a growth of +676% compared to 2023.

Revenue in France grew by 17%, totaling €4.12 million. Revenue in the United States reached €2.57 million in 2024, up +86% from €1.38 million in 2023. Export activity in the rest of the world also increased by 6% to €2.72 million in 2024, compared to €2.56 million in 2023.

Cash Position

As of December 31, 2024, the Company had a cash position of €1.60 million.

As a reminder, the Company received €0.68 million related to the sale of the MADISON^TM activity, with the remaining balance of €0.17 million expected to be collected during the first half of 2025. Additionally, on December 5, 2024, IMPLANET announced the implementation of financing with Shanghai Pudong Development Bank ("SPD Bank"). This financing arrangement consists of a short-term working capital loan from SPD Bank, totaling RMB 15.2 million (around €2 million), for a 12-month term, repayable in full at maturity, without requiring collateral. The loan is intended for supplier payments and other operational expenses, with repayment guaranteed by Sanyou Medical.

Given this recent financing and cash flow projections based on current activity assumptions and anticipated commercial developments with Sanyou Medical for the 2024 and 2025 fiscal years, the Company believes it will be able to meet its operational financing needs for the next twelve months. Additionally, the Company continues to explore various financing options to accelerate the development of its activities and medium-term growth, as well as the implementation of payment facilities with the Sanyou Medical group.

Reminder of 2024 highlights

• Successful completion of the capital increase announced on January 4, 2024, raising €5.5 million through the issuance of 83,924,897 new shares;

• Appointment of Max W. Painter as Vice President and General Manager of IMPLANET’s US subsidiary;

• FDA clearance of the new Jazz Spinal System^TM hybrid posterior fixation range in the United States;

• Exclusive partnership signed for the distribution of the ultrasonic scalpel Olea for endoscopic spine surgery in the U.S. market.

• Financing of around €2 million with Shanghai Pudong Development Bank.

Upcoming financial event:

• 2024 Full-Year Results: March 4, 2025, after market close.

About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery and distributing medical technology equipment. Its activity revolves around a comprehensive innovative solution for improving the treatment of spinal pathologies (JAZZ®) complemented by the product range offered by Orthopaedic & Spine Development (OSD), acquired in May 2021 (thoraco-lumbar screws, cages and cervical plates). Implanet’s tried-and-tested orthopedic platform is based on the traceability of its products. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States, the CE mark in Europe and ANVISA approval in Brazil. In 2022, IMPLANET entered into a commercial, technological and financial partnership with SANYOU MEDICAL, China's second largest medical device manufacturer. IMPLANET employs 43 staff and recorded a consolidated revenue of €9.4 million in 2024. Based near Bordeaux in France, IMPLANET opened a US subsidiary in Boston in 2013. IMPLANET is listed on the Euronext Growth market in Paris.
For further information, please visit www.Implanet.com.

Disclaimer
This press release contains forward-looking statements relating to IMPLANET and its activities. IMPLANET believes these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the forecasts expressed in these forward-looking statements will be realized, as they are subject to risks, including those described in IMPLANET’s registration document filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 16, 2018, under number D.18-0337, as well as in the annual financial report as of December 31, 2023, both available on the Company’s website (www.implanet-invest.com). These statements are also subject to changes in economic conditions, financial markets, and the markets in which IMPLANET operates. The forward-looking statements in this press release are also subject to risks that are unknown to IMPLANET or not currently considered material. The occurrence of some or all of these risks could cause IMPLANET’s actual results, financial condition, performance, or achievements to differ significantly from those expressed in these forward-looking statements.

This press release is for informational purposes only and does not constitute, and should not be considered as constituting, an offer to sell or subscribe to, or a solicitation of an offer to purchase or subscribe to, IMPLANET’s securities in any country.

¹ Unaudited figures

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114330809/en/

Contacts

IMPLANET
Ludovic Lastennet, CEO
David Dieumegard, CFO
Tél. : +33 (0)5 57 99 55 55
investors@Implanet.com

NewCap
Investor Relations
Nicolas Fossiez
Tél.: +33 (0)1 44 71 94 94
Implanet@newcap.eu

NewCap
Media Relations
Arthur Rouillé
Tél.: +33 (0)1 44 71 94 94
Implanet@newcap.eu